Company intelligence / Profile preview

Providence Therapeutics

Calgary, Alberta, Canadaprovidencetherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Their COVID-19 vaccine PTX-COVID19-B demonstrated high safety, efficacy and immunogenicity comparable to Pfizer/BioNTech's Comirnaty in Phase 2 trials. A Phase 3 trial is studying PTX-COVID19-B's superiority as a booster vaccine against AstraZeneca's Vaxzevria. Their bivalent mRNA vaccine has shown broad protection against multiple COVID-19 variants including Omicron XBB.1.5 and JN.1.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA therapeutics and vaccines
Industry: Biotech

Drug pipeline

14 assets

PTX-COVID19-B

13 more assets in the full pipeline.

Request access →

Partnerships

Biological E Limited (India)Everest Medicines Limited (China, terminated in 2024)Emergent BioSolutions Inc.Northern Therapeutics Inc.Genevant (LNP technology)

Beyond the preview

Go deeper on Providence Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Providence Therapeutics.

Explore the full profile